Financials data is unavailable for this security.
View more
Year on year Sichuan Kelun-Biotech Biopharmaceutical Co Ltd has grown net income from a loss of -616.10m to a smaller loss of -574.13m primarily through revenue growth (803.93m to 1.54bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales , the 91.62% growth in revenues contributed enough to still see net income improve.
| Gross margin | 61.81% |
|---|---|
| Net profit margin | -12.40% |
| Operating margin | -4.88% |
| Return on assets | -7.28% |
|---|---|
| Return on equity | -17.35% |
| Return on investment | -16.56% |
More ▼
Cash flow in CNYView more
In 2023, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd increased its cash reserves by 1,544.55%, or 1.44bn. Cash Flow from Financing totalled 2.38bn or 154.64% of revenues. In addition the company generated 59.56m in cash from operations while cash used for investing totalled 1.03bn.
| Cash flow per share | -0.7335 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 15.67 |
|---|---|
| Tangible book value per share | 15.66 |
More ▼
Balance sheet in CNYView more
| Current ratio | 5.70 |
|---|---|
| Quick ratio | 5.59 |
| Total debt/total equity | 0.0119 |
|---|---|
| Total debt/total capital | 0.0118 |
More ▼
